Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dr Reddy’s Laboratories ( (RDY) ) has issued an announcement.
On July 23, 2025, Dr. Reddy’s Laboratories announced the availability of audio recordings from their earnings call for the quarter ending June 30, 2025. The announcement is part of their regulatory compliance under the Securities and Exchange Board of India regulations, indicating transparency and communication with stakeholders. This move is likely to impact stakeholders by providing insights into the company’s financial performance and strategic direction.
The most recent analyst rating on (RDY) stock is a Buy with a $17.40 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The overall stock score for Dr Reddy’s Laboratories is solid, driven primarily by strong financial performance, indicating robust growth and stable operations. However, technical analysis suggests bearish momentum, and the valuation indicates limited dividend income potential, which slightly dampens the overall score.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is a global pharmaceutical company based in Hyderabad, India. The company is engaged in the manufacturing and marketing of a wide range of pharmaceuticals, including generic medications, active pharmaceutical ingredients, and proprietary products. Dr. Reddy’s serves markets worldwide, focusing on providing affordable and innovative medicines.
Average Trading Volume: 1,584,757
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.05B
For an in-depth examination of RDY stock, go to TipRanks’ Overview page.